Serine protease inhibitors

A compound having the structure shown below:

• where
• A and B are independently CH, CR3 or N;
• X is C═O or (CR4aR4b)m where m=1 or 2;
• Y is S(O)n—R1 where n=1 or 2, S(O)n—NR2R2 where n=1 or 2, S(O)n—OR2 where n 1 or 2, C(O)R1, C(S)R1, C(O)—OR1, C(O)—NR2R2;
• N1 and N2 are nitrogen atoms;
• Q and R1 are independently
• (1) optionally substituted alkyl having 1 to about 10 carbon atoms;
• (2) optionally substituted aralkyl containing an aryl moiety having 6 to about 10 ring carbon atoms bonded to an alkyl moiety containing 1 to about 10 carbon atoms;
• (3) optionally substituted heteroaralkyl containing a heteroaryl moiety having 5 to about 10 ring atoms bonded to an alkyl moiety having 1 to about 10 carbon atoms;
• (4) optionally substituted carbocycloalkyl containing a carbocyclyl moiety having 3 to about 10 ring carbon atoms bonded to an alkyl moiety having 1 to about 10 carbon atoms;
• (5) optionally substituted heterocycloalkyl containing a heterocyclyl moiety having 3 to about 10 ring atoms bonded to an alkyl moiety having 1 to about 10 carbon atoms;
• (6) optionally substituted alkenyl having 2 to about 10 carbon atoms;
• (7) optionally substituted aralkenyl containing an aryl moiety having 5 to about 10 ring atoms bonded to an alkenyl moiety having 2 to about 10 carbon atoms;
• (8) optionally substituted heteroaralkenyl containing a heteroaryl moiety having 5 to about 10 ring atoms bonded to an alkenyl moiety having 2 to about 10 carbon atoms;
• (9) optionally substituted carbocycloalkenyl containing a carbocyclyl moiety having 3 to about 10 ring carbon atoms bonded to an alkenyl moiety having 2 to about 10 carbon atoms;
• (10) optionally substituted heterocycloalkenyl containing a heterocyclyl moiety having 3 to about 10 ring atoms bonded to an alkenyl moiety having 2 to about 10 carbon atoms;
• (11) optionally substituted aryl having 6 to about 10 ring carbon atoms;
• (12) optionally substituted heteroaryl having 5 to about 10 ring atoms with ring atoms selected from carbon atoms and heteroatoms, where the heteroatoms are nitrogen, oxygen or sulfur;
• (13) optionally substituted carbocyclyl having 3 to about 10 ring carbon atoms;
• (14) optionally substituted heterocyclyl having 3 to about 10 ring atoms with ring atoms selected from carbon atoms and heteroatoms, where the heteroatoms are nitrogen, oxygen or sulfur;
• each R2 is, independently, H, alkyl, substituted alkyl, C(O)R7 or C(NH)R7, or N1R2 and N2R2 are together form the group N1—CO—N2;
• R3 is H, C1-C6 alkyl, C1-C6 alkoxy, halogen or OH;
• R4a and R5 are, independently, a member selected from the group consisting of H, unsubstituted or substituted alkyl, unsubstituted or substituted alkoxyalkyl, unsubstituted or substituted haloalkyl, unsubstituted or substituted aryl, alkyl-OR7, alkyl-NR7R8, alkyl-OC(O)R7, alkyl-C(O)OR7, alkyl-C(O)R7OC(O)R7, C(O)OR7, C(O)R7 and members in which the alkyl, R7 or R8 is substituted with 1-3 F, Cl, Br, I, OR7, SR7, NR7R8, OC(OR7), C(O)OR7, C(O)R7, C(O)NR7R8, NHC(NH)NH2, PO3, unsubstituted or substituted indolyl or unsubstituted or substituted imidazolyl groups;
• R4b is H, alkyl, or substituted alkyl;
• R6 is selected from the group selected from H, C1-C6 alkyl, C1-C6 alkyl-OR7, C1-C6 alkyl-N R7R8, C1-C6 haloalkyl, halo, cyano, OR7, SR7, NR7R8, C(O)OR7, C(O)R7 and OC(O)R7;
• R7 and R8 are independently H or C1-C6 alkyl;
• and acid and base addition salts and prodrugs thereof.